Jobert Anjelo, Rao Nitesh, Deayton Sue, Bennett Greg D, Brealey John, Nolan James, Carroll Robert P, Dragun Duska, Coates Patrick T
Royal Adelaide Hospital, Adelaide, South Australia, Australia.
Nephrology (Carlton). 2015 Mar;20 Suppl 1:10-2. doi: 10.1111/nep.12421.
Atypical non HLA antibodies are increasingly recognised as causes of immunological injury in allotransplantation. In this report we describe a non HLA sensitized male renal allograft recipient who developed acute vascular rejection on a "for cause" biopsy (Banff v2, g2, ptc 3) at day 4 post first renal allograft in the presence of elevated angiotensin II type 1 receptor antibodies (AT1R-Ab level 14.1). The acute rejection was treated with pulse corticosteroid therapy, anti-thymocyte globulin (ATG × 6), plasma exchange (1.5 plasma volume replacement x6) and oral candesartan. Serum creatinine improved and follow up biopsy confirmed resolution of rejection following treatment. AT1R-Ab should be considered when rejection is diagnosed in the absence of HLA antibodies.
非典型非HLA抗体日益被认为是同种异体移植中免疫损伤的原因。在本报告中,我们描述了一名非HLA致敏的男性肾移植受者,其在首次肾移植后第4天进行的“因症”活检(班夫分类v2,g2,ptc 3)时发生急性血管排斥反应,同时存在血管紧张素II 1型受体抗体升高(AT1R-Ab水平为14.1)。急性排斥反应采用脉冲皮质类固醇疗法、抗胸腺细胞球蛋白(ATG×6)、血浆置换(1.5倍血浆容量置换×6)和口服坎地沙坦进行治疗。血清肌酐水平改善,随访活检证实治疗后排斥反应消退。当在没有HLA抗体的情况下诊断出排斥反应时,应考虑AT1R-Ab。